Sunshine Biopharma Inc
SBFMW0.140USD
0.0000.00%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Sunshine Biopharma Inc Company
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
Sunshine Biopharma Inc Info
Ticker SymbolSBFMW
Company nameSunshine Biopharma Inc
IPO dateAug 15, 2008
CEODr. Steve N. Slilaty
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address333 Las Olas Way
CityFORT LAUDERDALE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33301
Phone19543300684
Websitehttps://www.sunshinebiopharma.com/
Ticker SymbolSBFMW
IPO dateAug 15, 2008
CEODr. Steve N. Slilaty
Company Executives of Sunshine Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
5
35.66K
0.00%
-9.61K
2025Q3
4
45.08K
0.00%
-15.49K
2025Q2
5
60.37K
0.00%
+5.15K
2025Q1
5
60.37K
0.00%
+5.15K
2024Q4
5
42.72K
0.00%
-18.68K
2024Q3
5
47.02K
0.00%
-38.45K
2024Q2
6
87.95K
0.00%
-8.56K
2024Q1
6
84.02K
0.00%
-7.28K
2023Q4
6
78.99K
0.00%
-17.09K
2023Q3
6
83.78K
0.00%
-60.47K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Clear Street Group Inc
94.00
0%
+94.00
--
Sep 30, 2025
Citadel Advisors LLC
12.07K
0%
-8.34K
-40.86%
Sep 30, 2025
UBS Financial Services, Inc.
23.40K
0%
-1.17K
-4.74%
Sep 30, 2025
Clear Street LLC
94.00
0%
--
--
Jun 30, 2025
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Sunshine Biopharma Inc?
The top five shareholders of Sunshine Biopharma Inc are:
Clear Street Group Inc holds 94.00 shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 12.07K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 23.40K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 94.00 shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 94.00 shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 12.07K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 23.40K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 94.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Sunshine Biopharma Inc?
The top three shareholder types of Sunshine Biopharma Inc are:
Other
Other
How many institutions hold shares of Sunshine Biopharma Inc (SBFMW)?
As of 2025Q4, 5 institutions hold shares of Sunshine Biopharma Inc, with a combined market value of approximately 35.66K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Sunshine Biopharma Inc?
In --, the -- business generated the highest revenue for Sunshine Biopharma Inc, amounting to -- and accounting for --% of total revenue.
